摘要
非小细胞肺癌(NSCLC)已经进入分子靶向治疗时代。表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)在NSCLC治疗中起重要作用,但EGFR-TKIs治疗过程中会不可避免地产生耐药。近年来,研究发现间变性淋巴瘤激酶(ALK)相关的融合基因是NSCLC的重要驱动基因而成为治疗的新靶点。本文就ALK融合基因以及ALK抑制剂对ALK融合基因阳性的NSCLC治疗进展作一综述。
Molecular targeted therapy has become an important therapeutic modality for non-small cell lung cancer（ NSCLC）.Epidermal growth factor receptor tyrosine kinase inhibitors（ EGFR-TKIs） have been reported to exert a significant impact in the treatment of NSCLC.However,patients eventually develop drug resistance to EGFR-TKIs.Recently,anaplastic lymphoma kinase（ ALK） fusion gene has been described as important driver gene in a subset of patients with NSCLC and becomes the new targets for NSCLC treatment.This paper reviewed the ALK fusion gene and progress of ALK inhibitors for the treatment of ALK fusion gene positive NSCLC patients.
作者
胡萍
张运剑
Ping ZHANG Yun-jian(Department of Respiratory and Critical Care Medicine, Beijing Jishuitan ,Hospital, Peking/University Fourth School of Clinical Medicine, Beijing 100035, China)
出处
《中国全科医学》
CAS
北大核心
2017年第2期232-236,共5页
Chinese General Practice
基金
国家自然科学基金资助项目(91543124)
北京市科学技术委员会资助课题(Z141107002514153)
关键词
癌
非小细胞肺
分子靶向治疗
间变性淋巴瘤激酶
基因融合
Carcinoma
non-small-cell lung
Molecular targeted therapy
Anaplastic lymphoma kinase
Gene fusion
